The FcγRIIIa-V158F polymorphism was shown to have diverse clinical implications, including susceptibility to autoimmune disorders, infectious diseases [24,25], and predicting therapy responses to mAbs [26,27,28,29], cancer vaccinations [30] and oncolytic adenoviruses [31]. The gene discussed is FCGR3A; the disease is cancer.